Skip to main content
. 2021 Jan 27;39(4):273–284. doi: 10.1200/JCO.20.02088

FIG 3.

FIG 3.

Progression-free survival by blinded independent central review. (A) ENCO/BINI/CETUX versus control. (B) ENCO/CETUX versus control. ENCO/BINI/CETUX, encorafenib, binimetinib plus cetuximab; ENCO/CETUX, encorafenib plus cetuximab; HR, hazard ratio; PFS, progression-free survival.